Overview
TRVI market data
Price History
TRVI price chart · 1M
- O
- 17.65
- H
- 18.11
- L
- 17.63
- C
- 18.11
- Vol
- 33,975.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $17.65
- Previous Close
- $17.93
- Day High
- $18.11
- Day Low
- $17.63
- 52 Week High
- $20.14
- 52 Week Low
- $13.13
- 7 Day Return
- -0.85%
- 30 Day Return
- -1.76%
- 90 Day Return
- +28.04%
- 1 Year Return
- +31.01%
- Daily Notional Volume
- $615.1K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.32 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.92 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.93 – $20.22 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.6B · P/B 8.76.
Company News
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28Benzinga · Aug 14, 2026, 12:52 PM
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25Benzinga · Aug 7, 2026, 3:21 PM
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30Benzinga · Aug 7, 2026, 12:09 PM
Trevi Therapeutics Q2 EPS $(0.11), InlineBenzinga · Aug 6, 2026, 8:12 PM
Trevi Therapeutics to Participate in Upcoming August ConferencesGlobenewswire Inc · Jul 28, 2026, 12:15 PM
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For TuesdayBenzinga · Jul 21, 2026, 3:14 PM
Trevi Therapeutics shares are trading higher after BMO Capital initiated its coverage on the stock with an Outperform rating and announced a price target of $36.Benzinga · Jul 21, 2026, 2:32 PM
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jul 21, 2026, 11:58 AM
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36Benzinga · Jul 21, 2026, 10:06 AM
B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31Benzinga · Jul 20, 2026, 1:36 PM